Bronchial Provocation Test Using AMP and Methacholine in Subjects with Asthma and COPD, Healthy Smokers and Non-Smokers

Basit Öğe Kaydı
dc.authoridAytemur, Zeynep Ayfer/0000-0003-0421-907X
dc.authorwosidAytemur, Zeynep Ayfer/ABI-7452-2020
dc.contributor.authorToros, Asli
dc.contributor.authorSolak, Zeynep Ayfer
dc.contributor.authorErdinc, Munevver
dc.contributor.authorKokuludag, Ali
dc.date.accessioned2024-08-04T20:57:19Z
dc.date.available2024-08-04T20:57:19Z
dc.date.issued2008
dc.departmentİnönü Üniversitesien_US
dc.description.abstractA direct stimulus such as methacholine is generally used to measure bronchial hyperresponsiveness. AMP, an indirect airway challenge, has been reported to be a better marker of inflammation than direct challenges and can be used in the differential diagnosis of asthma from other airway diseases. In this study, the effects of bronchial provocation test (BPT) using AMP and methacholine were compared in patients with asthma and COPD as well as healthy smokers and non-smokers. The study population consists of 60 subjects including 16 with mild asthma, 14 with mild-moderate COPD (8 current smokers and 6 ex-smokers), 15 non- smokers, and 15 current smokers. All the subjects underwent BPT using AMP and methacholine. 14 (87.5%) patients with asthma and seven (50%) patients with COPD were AMP responsive at a concentration of PC20 <= 100mg/ml (p=0.046). When asthmatic patients and current smokers with COPD were compared to each other, no significant difference was found related toAMP and methacholine responsiveness. However, one (16.7%) ex-smoker with COPD and 14 ( 87.5%) patients with asthma were AMP responsive at a concentration of PC20 <= 100mg/ml (p=0.004). Re-evaluated at an AMP concentration of PC20 <= 800mg/ml, 15 asthmatics (93.8%) and two ex-smokers with COPD(33.3%) were assessed to be hyperresponsiveness to AMP (p= 0.009). Patients with COPD were more responsive to the maximal concentration of both AMP and methacholine than healthy smokers (p= 0.008, p= 0.009). Provocation test using AMP is more sensitive than methacholine in the differentiating diagnosis of airway inflammation in asthma and COPD and being a current smoker may increase inflammation, and thus the AMP responsiveness in COPD.en_US
dc.identifier.endpage26en_US
dc.identifier.issn1302-7808
dc.identifier.issn1308-5387
dc.identifier.issue1en_US
dc.identifier.startpage22en_US
dc.identifier.urihttps://hdl.handle.net/11616/102505
dc.identifier.volume9en_US
dc.identifier.wosWOS:000421642400005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isotren_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Thoracic Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectadenosine challengeen_US
dc.subjectmethacholine challengeen_US
dc.subjectbronchial hyperre-sponsivenessen_US
dc.subjectasthmaen_US
dc.subjectCOPDen_US
dc.titleBronchial Provocation Test Using AMP and Methacholine in Subjects with Asthma and COPD, Healthy Smokers and Non-Smokersen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu